NCT05773872 Evaluation of Social Cognition in Patient With Type 1 or Type 2 Narcolepsy Versus Patients With Idiopathic Hypersomnia
| NCT ID | NCT05773872 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire, Amiens |
| Condition | Narcolepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2022-11-18 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2022-11-18 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Narcolepsy is a chronic disabling neurologic disorder mainly characterised by excessive daytime sleepiness. Type 1 narcolepsy is associated with a deficit of hypocretin in the cerebrospinal fluid responsible for the cataplexy symptom while type 2 shows a normal hypocretin level and no cataplexy. While the development of narcolepsy is independent of parental social level, narcolepsy has a significant influence on educational level, grading, social outcome, and welfare consequences. Several studies assessed global cognition efficiency, mood, and attention in narcoleptic patients but only a few specifically measured social cognition and mostly without a control group. In a population of narcoleptics children, a severe impairment in social cognition is described for 20% of the group, contrary to 2 % for the control group. The literature also depicts some impairments in decision making, somatic and cognitive emotions responses but the emotion recognition seems to be preserved. A better understanding of the social and cognitive aspects of narcolepsy could lead to a better treatment of the disease in its entirety, including if relevant specific cognitive behavioural therapy. The protocol consists in a psychometric evaluation including several questionnaires in order to assess social cognition. It will be proposed to patients with type 1 or type 2 narcolepsy and patients with idiopathic hypersomnia.
Eligibility Criteria
Inclusion Criteria: * adult patients (\>/= 18years old) * diagnosis of type 1 or type 2 narcolepsy or idiopathic hypersomnia * non opposition Exclusion Criteria: * comorbid psychiatric or neurologic disease * patient under 18 years old * patient under guardianship, curators or deprived of liberty, refusal of the patient
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05773872 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Narcolepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05773872 currently recruiting?
Yes, NCT05773872 is actively recruiting participants. Contact the research team at Flamand.mathilde@chu-amiens.fr for enrollment information.
Where is the NCT05773872 trial being conducted?
This trial is being conducted at Amiens, France.
Who is sponsoring the NCT05773872 clinical trial?
NCT05773872 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 75 participants.